KRAS and neoplasm: Additionally, several studies using paraffin-embedded tumor samples and detection technologies less sensitive than ddPCR reported the concomitant presence of KRAS and BRAF mutations, but in a lower percentage (below 4%) [34,35] than that found in our study.